Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Spinal Cord Neoplasms 1Pinealoma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Choroid Plexus Carcinoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 101Radiotherapy 50Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 23Bevacizumab 23Lomustine 16Nivolumab 14Surgical Procedures, Operative 11atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7Carboplatin 7fludarabine 6Radiotherapy, Intensity-Modulated 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5regorafenib 4poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × perillyl alcohol × 1 year × Clear all
NCT02704858 2026-03-02

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Neonc Technologies, Inc.

Phase 1/2 Recruiting
49 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡